Clinical Trial Update: Pro-adrenomedullin as a Prognostic Marker in Neonatal Sepsis

View source ↗

Summary

A completed clinical trial evaluated pro-adrenomedullin as a prognostic biomarker in neonatal sepsis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Sepsis

Snippet

Sponsor: Zekai Tahir Burak Women's Health Research and Education Hospital | Conditions: Sepsis | Status: COMPLETED